Abstract
Background The social motivation hypothesis of autism suggests that autism spectrum disorder (ASD) is characterized by impaired motivation to seek out social experience early in life that interferes with the development of social functioning. This framework posits that impaired mesolimbic dopamine (DA) function underlies compromised responses to social rewards in ASD. Although this hypothesis is supported by functional magnetic resonance imaging (fMRI) studies, no molecular imaging study has evaluated striatal dopamine functioning in response to rewards in ASD.
Methods This study evaluated striatal dopaminergic functioning during incentive processing in ASD using simultaneous positron emission tomography (PET) and fMRI using the D2/D3 dopamine receptor antagonist [11C]raclopride. Using a bolus + infusion protocol, voxel-wise binding potential (BPND) was compared between groups (Controls=12, ASD=10) in the striatum.
Results Relative to controls, the ASD group demonstrated relatively decreased phasic DA release to incentives in the right and left putamen and left caudate. Striatal clusters showing significant between-group BPND differences were used as seeds in whole-brain fMRI general functional connectivity analyses. This revealed increased connectivity between the PET-derived right putamen seed and clusters in the precuneus and right insula in the ASD group. Within the ASD group, decreased phasic DA release in the left putamen was related to poorer theory-of-mind skills.
Conclusions ASD was characterized by impaired striatal phasic DA release and abnormally increased functional connectivity, providing support for the social motivation hypothesis of autism. PET measures of dopamine receptor target occupancy may be suitable to evaluate novel ASD therapeutics targeting the striatal dopamine system.
Competing Interest Statement
Over the past three years, Dr. Pizzagalli has received funding from NIMH, Brain and Behavior Research Foundation, the Dana Foundation, and Millennium Pharmaceuticals; consulting fees from Akili Interactive Labs, BlackThorn Therapeutics, Boehreinger Ingelheim, Compass Pathway, Posit Science, Otsuka Pharmaceuticals, and Takeda Pharmaceuticals; one honorarium from Alkermes; stock options from BlackThorn Therapeutics. All other authors report no biomedical financial interests or potential conflicts of interest.
Funding Statement
This research was supported by R21 MH110933 to GSD and JMH, K23 MH113733 to ECW, and UL1TR002489. Assistance with recruitment was provided by the Clinical Translational Core of the UNC Intellectual Developmental Disabilities Research Center (HD103573).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The original research described in this manuscript was conducted in in accordance with the ethical standards of the University of North Carolina at Chapel Hill (UNC) Institutional Review Board and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The PET protocol was approved by the UNC Radioactive Drug Research Committee.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data from this study are available for download from the National Database for Autism Research (NDAR), collection #2471
